Accent Therapeutics raised $75 million in a series C round, with investments from Bristol Myers Squibb and Johnson & Johnson’s investment arm, JJDC, led by Mirae Asset Capital Life Science. The funding will drive further development of the company’s lead small molecules and advance them into human trials.

Mirae Asset Capital Life Science

Johnson & Johnson

Bristol Myers Squibb

Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.




Two more pharmas practice their Accent, invest in $75M series C round

Two more pharmas practice their Accent, invest in $75M series C round

Company Info

Related People